Protalix BioTherapeutics (PLX) Convertible Debt (2013 - 2023)

Protalix BioTherapeutics' Convertible Debt history runs 11 years deep, the most recent figure standing at $20.4 million for Q4 2023.

• On a quarterly basis, Convertible Debt fell 27.56% year-over-year to $20.4 million in Q4 2023; TTM through Dec 2023 was $20.4 million, a 27.56% decrease from a year earlier, with the FY2023 full-year figure at $20.4 million, down 27.56% from the prior year.
• Convertible Debt rose to $20.4 million in Q4 2023 per PLX's latest filing, from $20.1 million in the prior quarter.
• Across five years, Convertible Debt topped out at $53.5 million in Q3 2020 and bottomed at $20.1 million in Q2 2023.
• The 5-year median for Convertible Debt is $28.2 million (2022), against an average of $37.1 million.
• Across the five-year window, Convertible Debt advanced 6.66% in 2020 and tumbled 48.01% in 2021, its largest moves.
• Year by year, Convertible Debt stood at $51.0 million in 2019, then advanced by 5.0% to $53.5 million in 2020, then slumped by 47.88% to $27.9 million in 2021, then increased by 1.08% to $28.2 million in 2022, then dropped by 27.56% to $20.4 million in 2023.
• Per Business Quant, the three latest PLX Convertible Debt figures stand at $20.4 million (Q4 2023), $20.1 million (Q2 2023), and $28.3 million (Q1 2023).